Navigation Links
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
Date:7/2/2009

TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows:

1. Sustained Release Tablets

Eisai has completed a Phase III study of Aricept 23 mg sustained release (SR) in patients with moderate to severe Alzheimer's disease. Aricept 23 mg SR is being developed to increase clinical benefits while maintaining a favorable safety profile compared to currently marketed Aricept 10 mg immediate release.

Based on the preliminary review of the data from this Phase III study, Eisai plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in August or September 2009.

2. Pediatric Use

Eisai filed a Proposed Pediatric Study Request (PPSR), an application that proposes a rationale and study design for pediatric studies, with the U.S. FDA in February 2009 to evaluate the clinical benefits of donepezil in children with attention impairment following cancer treatment. Eisai received a notice from the U.S. FDA that there were insufficient grounds to issue a Written Request to obtain pediatric exclusivity. Eisai plans to complete the ongoing studies to provide important information on this therapeutic approach for an underserved patient population currently with limited treatment options.

3. Transdermal Patch Formulation

Clinical trials of a once-a-week transdermal patch formulation of donepezil, which include a bioequivalence study compared to the currently markete
'/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
4. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
5. Angiomax Will Retain Decision Resources Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
6. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
7. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
8. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
9. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
10. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Roughly three-quarters ... very confident substituting an interchangeable biosimilar for its ... the same nonproprietary name, according to a survey ... (AMCP,s) Journal of Managed Care & Specialty ... 25 percent of pharmacists would feel as confident ...
(Date:2/27/2015)... Feb. 27, 2015  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: VTAE ).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On February 27, 2015, the Company ...
(Date:2/27/2015)... February 27, 2015 ... dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF - ...     Vectorious ... nuovo sistema per il monitoraggio cardiaco destinato a ... oggi di aver concluso una raccolta di finanziamenti ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... FREMONT, Calif., Nov. 19 Quark Pharmaceuticals, Inc., the leader ... its siRNA R&D platform based programs have met clinical development ... a new IND opened for ocular neuroprotection drug candidate QPI ... has completed enrollment in a Phase 2 study of PF-4523655 ...
... Nov. 19 Radiall and Integral Process will collaborate in ... agreement to confirm this new alliance. , Radiall has a ... time, the company has established relationships with major players in ... , Integral Process is a key supplier of interconnect ...
Cached Medicine Technology:Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 2Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 3Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 4Radiall and Integral Process Sign Agreement 2
(Date:3/1/2015)... Indiana (PRWEB) March 01, 2015 ... statewide Network Service Provider, announces NewWays Networking, LLC ... “By working with IFN, NewWays is well ... meet client’s demand for Internet bandwidth in rural ... , According to Cory Childs IFN Enterprise ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... February 28, 2015 Vancouver personal injury lawyers ... claims are affected by time limits. They stated that in ... person’s claim or even nullify it. Many a time, delays ... a client’s rights under BC law. As a result, experts ... by accidents should consult a personal injury lawyer in order ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... data from previously completed withdrawal to monotherapy studies for ... studies, obviating the need for placebo/pseudo-placebo trials to demonstrate ... this study are now available online in Epilepsia ... the International League Against Epilepsy. According to a ...
... is available in French . Montreal, ... Heart Institute (MHI) has shown unexpectedly that living with children ... with 756 participants and led by Dr. Simon L. Bacon, ... the study assessed the impact of social networks on exercise, ...
... lives of infants and children with developmental disabilities will ... Developmental Disabilities Research Center (WUIDDRC). The center, established ... National Institutes of Health (NIH), will focus on research ... emphasis will be placed on clinical and translational research ...
... 2010 - Janice Morse, RN, PhD, FAAN, a professor ... inducted into the newly created Sigma Theta Tau International ... researchers who have achieved long-term, broad national and/or international ... research has impacted the profession and the people it ...
... the skin cancer melanoma appear different in Florida than ,from ... non-Hispanic black women but lower rates among Hispanic women, according ... of Dermatology, one of the JAMA/Archives journals. "In ... than that of any other cancer," the authors write as ...
... , MONDAY, July 19 (HealthDay News) -- Children conceived using ... than do children who were conceived naturally, new research shows. ... increased by 42 percent for Swedish youngsters conceived with IVF, ... "We found a roughly 50 percent increased risk for cancer ...
Cached Medicine News:Health News:FDA accepts historical controls for epilepsy monotherapy studies 2Health News:FDA accepts historical controls for epilepsy monotherapy studies 3Health News:Concordia researcher leads study that finds kids reduce physical activity for heart patients 2Health News:Developmental disabilities center established at Washington University 2Health News:U of U's Janice Morse inducted into International Nurse Researcher Hall of Fame 2Health News:Melanoma rates among minorities in Florida differ from national trends 2Health News:Study Suggests Higher Cancer Rate Among IVF Babies 2Health News:Study Suggests Higher Cancer Rate Among IVF Babies 3
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Medicine Products: